

# **CONSOLIDATED ACTIVITY REPORT**

For the first quarter  
of 2026



**TCHAIKAPHARMA**  
**HIGH QUALITY MEDICINES**

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.

22.05.2026

## **General information about Tchaikapharma High Quality Medicines Inc.-Group**

### **1. Economic activity**

The entered in the Commercial Register activity of the Company is: purchase of substances and formulations for the production and sale of pharmaceuticals in finished or processed form, (after Marketing Authorisation); primary and secondary packaging of formulations (after Marketing Authorisation); import, export, re-export and merchandising in original or processed form; barter transactions and commissions; commercial representation of foreign and domestic individuals and legal entities at home and abroad; industrial and commercial management; consulting, marketing, brokerage, leasing, licensing, entrepreneurship, transport and shipping, research and development activities.

Currently the main scope of activity of the Company can be summarized as follows:

- Production
- Packaging (primary and secondary)
- Marketing and promotion of medicines
- Research and Development

Tchaikapharma High Quality Medicines Inc. continuously maintains its production facilities in accordance with the contemporary European requirements for Good Manufacturing Practice in the production of medicines. At present, more than 160 medicinal products are produced in the company's factories. The premises and the equipment of the factories are executed in full compliance with the European requirements for the production of medicines and for the plant in Varna – also for sterile medicinal products.

### **2. Foundation date and duration in time**

The Company was founded and entered in the Commercial Registry by Decision from 14.03.2000 on the company case 1096/2000 of the Varna District Court as a joint stock company. The duration of the Company is not limited in time.

"Tchaikapharma High Quality Medicines" Inc. is a public company according to the Public Offering of Securities Act of 21.05.2015.

### **3. Controlled companies**


As of 31.03.2026 it has one wholly-owned subsidiary: SWYSSI S.R.L. registered in the Republic of Romania and on 21.02.2024 registered a second subsidiary, PERPETEL EAD.

### **4. Board of Directors**

Tchaikapharma High Quality Medicines Inc. has a one-tier management system with a Board of Directors of three members. The management of the parent company in the person of the Board of Directors as of 31.03.2026 is composed of:

Biser Rosenov Georgiev	Chairman
Sylvia Slavcheva Patrikova	Member
Radka Alexandrova Tsenova	Member

## 5. Shareholding structure 31.03.2026.



## 6. Employees

As of 31.03.2026, the average number of employees in Tchaikapharma High Quality Medicines Inc. Group is 214 people, who are entirely in the parent company.

## II. Development of the activity

### Investments

#### Major investments in the first quarter of 2026.

Overview of the investments in fixed assets by type and year is presented in the following table.

<b>Investments for the period</b>	<b>2023</b>	<b>2024</b>	<b>2025</b>
<b>Tchaikapharma High Quality Medicines Inc.</b>	<i>EUR'000</i>	<i>EUR'000</i>	<i>EUR'000</i>
<b>I. Fixed tangible assets</b>	<b>336</b>	<b>709</b>	<b>391</b>
1. Land and buildings	81	17	0
2. Property and equipment	182	691	391
3. Other fixed assets	74	1	1
<b>II. Fixed intangible assets</b>	<b>44</b>	<b>5</b>	<b>253</b>
1. Industrial property rights	24	3	67
2. Software	20	2	6
3. Patents and licenses	0	0	180
<b>Total amount of acquisition of fixed tangible and intangible assets</b>	<b>380</b>	<b>714</b>	<b>644</b>

### Major investments in progress

The company invested in the purchase of a machine for visual inspection of each vial in order to optimize the production process and speed up the release of the finished product. Installation at the Varna plant has been completed and the machine has been put into operation. At the end of 2024, the company began manufacturing food supplements, and by December 2025, EUR 33 thousand packages had been sold on the market.

### KEY FINANCIAL INDICATORS

<b>Indicators</b>	<b>01-03/2026</b>	<b>01-03/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>
Sales revenue	9 621	8 277
Earnings before interest, taxes and depreciation (EBITDA)	2 381	1 644
Net profit	1 829	1 108
	<b>01-03/2026</b>	<b>01-03/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>
Non-current assets	22 072	22 336
Current assets	51 532	50 237
Equity	61 458	59 629
Non-current liabilities	1 484	1 608
Current liabilities	10 662	11 336

	01-03/2026	01-03/2025
EBITDA/Sales revenue	25%	20%
Net profit/Sales revenue	19%	13%

## Review of the risk factors

- The Company's activities could be affected by any change in the regulatory requirements for the production of pharmaceutical products.
- Changes to the legislation regulating the Company's business are possible, and these can potentially increase the costs of compliance or have another effect on its operations.
- The production processes of the Company are subject to stringent requirements and approvals by regulatory authorities which may delay or interrupt the operations of the Company.
- The ability of the Company to pay dividends depends on a number of factors and there is no guarantee that in a year it will be able to pay dividends in accordance with its dividend policy.
- The Company is exposed to operational risk, which is inherent in its business activities.
- The Company is subject to multitude laws and regulations in the field of environmental protection and health and safety conditions and is exposed to potential liabilities related to the environment.
- The Company is exposed to strong competition.
- The Company operates in active exchange with foreign suppliers and customers. It is therefore exposed to currency risk, mainly against the US dollar. Currency risk is related to the adverse movement in the exchange rate of the US dollar against the Bulgarian lev in future business operations, recognized foreign currency assets and liabilities. The rest of the company's operations are usually denominated in Bulgarian lev and/or in euros.

## Sales by types of dosage forms

Revenue by dosage forms	01-03/2026 EUR'000	01-03/2025 EUR'000
Tablets	7 837	6 636
Ampules	18	147
Vials	1 764	1 476
<b>Total:</b>	<b>9 619</b>	<b>8 259</b>

Revenue by therapeutic groups	01-03/2026 EUR'000	01-03/2025 EUR'000
Cardiovascular system	6 530	5 262
Musculoskeletal system and connective tissue	26	25
Respiratory system and antibiotics	964	816
Nervous system	155	150
Endocrine system	730	727

Other products	912	980
Digestive system and metabolism	190	102
Food supplements	112	69
Oncology	-	130
<b>Total:</b>	<b>9 619</b>	<b>8 259</b>

<b>Changes in the inventories of products and work in progress</b>	<b>433</b>	<b>(148)</b>
--	------------	--------------

<b>Other operating income</b>	<b>01-03/2026</b>	<b>01-03/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>

Income from rent	2	2
Other income	-	16
<b>Total:</b>	<b>2</b>	<b>18</b>

<b>Financial income</b>	<b>01-03/2026</b>	<b>01-03/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>

Income from interest	-	-
Income from exchange rate differences	5	6
<b>Total:</b>	<b>5</b>	<b>6</b>

## Core activity expenses

<b>Operating expenses</b>	<b>01-03/2026</b>	<b>01-03/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>

Book value of sold products	329	506
Materials	2 201	1 897
External services	3 612	2 684
Salaries	1 177	1 121
Social security costs	230	205
Depreciation costs	382	361
Other	106	87
<b>Total:</b>	<b>8 037</b>	<b>6 862</b>

<b>Cost of materials</b>	<b>01-03/2026</b>	<b>01-03/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>

Basic material	1 975	1 670
Electricity	120	107
Fuels and lubricants	34	31
Spare parts and laboratory materials	24	35
Water	5	4
Other materials	43	50

<b>Total:</b>	<b>2 201</b>	<b>1 897</b>
---------------	--------------	--------------

<b>Costs of external services</b>	<b>01-03/2026</b>	<b>01-03/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>

Security	94	81
Insurance	5	4
Telephone and postage expenses	3	5
Equipment maintenance and subscription	33	30
Fees	16	52
Transport costs	6	7
Other costs for external services	3 455	2 506
<b>Total:</b>	<b>3 612</b>	<b>2 684</b>

<b>Financial expenses</b>	<b>01-03/2026</b>	<b>01-03/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>

Interest expenses	50	63
Expenses from exchange rate differences	21	12
Other financial expenses	2	3
<b>Total:</b>	<b>73</b>	<b>78</b>

## Assets

	<b>01-03/2026</b>	<b>01-12/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>

### Non-current assets

Property, plant and equipment	17 582	17 889
Intangible assets	1 887	1 844
Trade receivables	2 603	2 603
<b>Total non-current assets</b>	<b>22 072</b>	<b>22 336</b>

### Current assets

Inventories	9 635	9 165
Trade and other receivables	41 796	40 465
Cash and cash equivalents	101	607
<b>Total current assets</b>	<b>51 532</b>	<b>50 237</b>
<b>Total Assets</b>	<b>73 604</b>	<b>72 573</b>

	<b>01-03/2026</b>	<b>01-12/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>

### Property, plant and equipment

Land and buildings	13 381	13 529
Machinery and equipment	4 133	4 205
Other	-	-
In the process of acquisition	68	155
	<b>17 582</b>	<b>17 889</b>

<b>Inventories</b>	<b>01-03/2026</b>	<b>01-12/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>
Materials	7 921	7 815
Production	802	411
Goods	912	940
<b>Total:</b>	<b>9 635</b>	<b>9 165</b>

### Equity and liabilities

	<b>01-03/2026</b>	<b>01-12/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>
Registered capital	49 033	49 033
Statutory reserve	7 525	7 525
Undistributed profit	4 900	3 071
<b>Total Equity</b>	<b>61 458</b>	<b>59 629</b>

### Liabilities

	<b>01-03/2026</b>	<b>01-12/2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>
<b>Non-current liabilities</b>		
Long-term loans	665	789
Deferred tax liabilities	637	637
Liabilities to employees on retirement	182	182
<b>Total non-current liabilities</b>	<b>1 484</b>	<b>1 608</b>

### Current liabilities

Trade and other liabilities	5 604	5 590
Short term loans	4 002	4 752
Current part of long-term loans	457	476
Current income tax	29	29
Other tax liabilities	570	489
<b>Total current liabilities</b>	<b>10 662</b>	<b>11 337</b>
<b>Total liabilities</b>	<b>12 146</b>	<b>12 944</b>
<b>Total equity and liabilities</b>	<b>73 604</b>	<b>72 573</b>

### Financial indicators

	<b>01-03/2026</b>	<b>01-12/2025</b>
Leverage ratio	0.20	0.22
Financial autonomy ratio	5.06	4.61

## Information on the shares of Tchaikapharma High Quality Medicines Inc.-Group

The total amount of shares issued as of 31.03.2026 was 95 900 000 with a nominal value of EUR 0.51 per share. All issued shares are registered, dematerialized, ordinary and indivisible under the Statute of the Company. All issued shares are of the same type. Each share gives equal rights to its owner in proportion to the nominal value of the share. The shares of Tchaikapharma High Quality Medicines Inc. are traded on the official market of the Bulgarian Stock Exchange-Sofia.

## Essential information on the shares of Tchaikapharma High Quality Medicines Inc.-Group

	<b>1-03/2026</b>	<b>1-12/2025</b>
Total number of issued shares	95 900 000	95 900 000
Number of shares in circulation at end of period	95 900 000	95 900 000
Price per share at the end of the period in EUR	9.35	9.40
Market capitalization at the end of the period in EUR	896 665 000	901 460 000

Biser Georgiev

/Executive Director/

